TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition

Estimated reading time: 9 minutes

Key takeaways

In a 26-week program of intensive diet and supervised exercise, TRT did not add to overall physical performance test scores but helped preserve lean mass and hip BMD.
TRT modestly improved VO₂peak and showed signals for cognitive benefit; gains tracked with changes in fitness, strength, and hormones.
Metabolomic data suggest TRT restores muscle glycolytic capacity, supporting metabolic flexibility during weight loss.
Both TRT and placebo groups improved triglycerides and metabolic syndrome scores with weight loss; TRT showed additional metabolic flexibility signals.
Findings are from a small, frail cohort over 26 weeks; long-term safety and durability remain uncertain.

The LITROS Trial at a Glance
What Did TRT Add Beyond Lifestyle?
Mechanism: Restoring Glycolysis and Metabolic Flexibility
Cognitive Outcomes
Why No Extra Boost in Physical Performance Tests?
Safety and Limitations
Practical Considerations
Who Might Be a Candidate?
Open Questions
Bottom Line

Older men with obesity and low testosterone often face a dilemma: how to lose weight without accelerating muscle and bone loss. The LITROS trial (NCT02367105) tested a pragmatic idea—pair medically guided weight loss and supervised exercise with testosterone replacement therapy (TRT)—to see whether TRT could protect lean mass and bone while improving other aging-related outcomes. The results are nuanced and clinically relevant for older obese men considering TRT as part of a structured program.

The LITROS Trial at a Glance

Who: 83 men aged 65+ with obesity (BMI ≥30 kg/m²), low testosterone (<10.4 nmol/L), and reduced function (Physical Performance Test ≤31)—a frail population.
Design: 26-week, double-blind, placebo-controlled trial of testosterone vs. placebo. All participants received intensive lifestyle intervention: diet targeting ~10% weight loss plus supervised aerobic and resistance training.
Goal: Determine whether adding TRT to optimized lifestyle meaningfully improves function, body composition, bone health, metabolism, and cognition in frail, hypogonadal, obese older men.

This design isolates what TRT adds when lifestyle is already optimized—mirroring real-world goals for losing weight without worsening sarcopenia or bone loss.

What Did TRT Add Beyond Lifestyle?

Lifestyle change drove clear improvements in both groups. The incremental effects of TRT were selective but meaningful.

Lean body mass: TRT attenuated loss (about −2% vs. −3% with placebo; P = 0.01), reducing sarcopenia risk during weight loss.
Thigh muscle volume: Smaller decline with TRT (about −2% vs. −4%; P = 0.04), potentially preserving strength reserve.
Hip bone mineral density: Shift from loss to preservation (+0.5% with TRT vs. −1.1% with placebo; P = 0.003).
Aerobic capacity (VO₂peak): Both groups improved; TRT produced a greater increase—an additive cardiorespiratory fitness effect.
Physical Performance Test (PPT): Similar improvements in both groups; no added composite functional gain with TRT at 26 weeks.
Metabolism: Triglycerides and metabolic syndrome scores improved with weight loss in both groups; TRT showed additional signals of metabolic flexibility.

Clinically, TRT functioned as a protective adjunct during intensive weight loss and training—helping keep muscle and bone “on board” while nudging aerobic conditioning.

Mechanism: Restoring Glycolysis and Metabolic Flexibility

A metabolomic substudy of LITROS found that TRT appeared to reprogram skeletal muscle toward greater glycolytic capacity—the ability to quickly generate energy from glucose—crucial during caloric restriction and training.

Glycolysis was the primary pathway consistently restored at six months in the TRT group.
This aligns with preserved lean mass and thigh muscle volume and may help explain the VO₂peak advantage.
The data suggest enhanced metabolic flexibility with TRT, supporting more adaptive responses to diet and exercise.

These insights clarify how TRT may counter weight loss–induced catabolism; whether adaptations persist after stopping TRT is unknown.

Cognitive Outcomes

Global cognition improved more with TRT than with lifestyle alone.
Predictors of cognitive gains included changes in VO₂peak, muscle strength, total testosterone, and luteinizing hormone—suggesting brain benefits tracked with systemic fitness and hormonal changes.

Cognitive outcomes were secondary and not powered for domain-specific effects after multiple-comparison adjustment, but the signal toward benefit in a structured program is noteworthy.

Why No Extra Boost in Physical Performance Tests?

Strong lifestyle effect: Both groups lost ~9% body weight and improved function; short-term floor/ceiling effects can obscure incremental gains.
Composite metric limits: PPT aggregates domains (walking, balance, transfers) that may respond more to practice or weight loss than to anabolic signals over six months.
Time horizon: Mechanistic advantages (glycolysis, lean mass, bone) may translate to longer-term resilience not captured at 26 weeks.

Safety and Limitations

Short duration, small size: 26 weeks; n=83. Durability after discontinuation is unknown.
Specific population: Predominantly male Veterans, 65+, obese, hypogonadal, frail—generalizability is limited.
Context matters: All participants pursued significant caloric restriction and supervised exercise; effects outside this setting are unclear.
Hard outcomes unassessed: Not powered for cardiovascular events, fractures, or prostate outcomes.
Mechanistic subset: Muscle metabolomics were performed in a subset; representativeness is uncertain.

Regulatory note: In the U.S., TRT approvals rely on achieving physiologic testosterone levels, not on demonstrated outcome improvements. LITROS provides investigator-driven outcome data for a specific population.

Practical Considerations

Lifestyle is foundational: Diet and supervised training drove most functional gains; view TRT (when indicated) as an adjunct to protect lean mass and bone and support aerobic capacity.
Expect selective benefits: Don’t expect large added improvements in everyday performance tests over six months; clearest TRT effects were on lean/thigh muscle, hip BMD, and modest VO₂peak gains.
Cognition tracks fitness: Cognitive improvements moved with aerobic fitness, strength, and normalized hormones.
Monitoring is essential: TRT requires labs and follow-up; optimal dosing and long-term risk–benefit remain open questions.
Individual variability: Responses differ; metabolomic data hint at potential “responders,” but prediction is not yet possible.
Time horizon: Six months is short in geriatrics; decisions should align with long-term goals and comorbidities.

Who Might Be a Candidate?

Men aged 65+ with confirmed clinical hypogonadism
Obesity and functional limitations consistent with frailty
Capacity and motivation for a structured weight loss and supervised exercise program for at least six months

Findings may not translate to non-frail older men, those unable to engage in structured lifestyle programs, or younger populations. Shared decision-making with a qualified clinician is essential.

Open Questions

Durability: Do muscle, bone, metabolic, and cognitive benefits persist beyond six months or require ongoing therapy/training?
Safety at scale: What are long-term cardiovascular, prostate, and thromboembolic risks/benefits in this high-risk population?
Dose optimization: Could lower doses achieve similar protection with fewer risks?
Generalizability: Would results replicate in more diverse, non-Veteran, or non-frail cohorts?
Mechanistic markers: Can glycolytic “responders” be identified to personalize therapy?
Value: Is adjunctive TRT cost-effective relative to monitoring and medication burden?

Bottom Line

For older obese men pursuing intensive, medically guided weight loss and supervised training, LITROS offers a measured message. Lifestyle change is the engine of improved physical performance. Adding TRT did not further raise composite performance scores over six months—but it did preserve lean muscle and hip bone density, modestly improved VO₂peak, supported metabolic flexibility via renewed glycolysis, and showed signals for cognitive benefit. These selective effects are relevant for frail seniors aiming to lose weight without sacrificing muscle and bone.

The data are promising yet preliminary: the trial was short, small, and not powered for hard safety outcomes. If you fit the LITROS profile, discuss goals, risks, and the commitment required for structured lifestyle change with your clinician.

Disclaimer

This article is for informational purposes only and is not medical advice. It does not diagnose, treat, or recommend any therapy. Decisions about testosterone therapy should be made with a qualified healthcare professional who can assess your individual situation.

TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition